Central Nervous System: Is creatine a CNS neurotransmitter?

A range of experiments suggests that creatine, a molecule known for recycling ATP in muscle and brain tissue, may also function as a neurotransmitter in the central nervous system.
  1. Bhagaban Mallik
  2. C Andrew Frank  Is a corresponding author
  1. Department of Anatomy and Cell Biology, University of Iowa, United States

Communication in the nervous system relies on neurons transmitting signals to target cells. This process is facilitated by various chemicals, including neurotransmitters, neuromodulators and neuropeptides (Langley, 1905; Benfenati and Agnati, 1991; Lovinger, 2008). Identifying a new neurotransmitter is no small feat: such a discovery requires extensive investigation and validation, and it might take decades to integrate the collective contributions of many different research groups (Hökfelt, 2010; Contestabile, 2011). Moreover, neurotransmitters that act in peripheral tissues, like muscle, are easier to identify than those that act on the central nervous system (CNS). It is likely that many CNS neurotransmitters have not yet been identified (Curtis et al., 1959; Carlsson et al., 1962; Curtis and Watkins, 1963; Björklund et al., 1968; Andersson, 2000).

To be classified as a neurotransmitter, a molecule should meet several criteria: it needs to be stored within a synaptic vesicle in a neuron and be released upon neuronal stimulation; it needs to act upon a postsynaptic receptor; and afterwards, it needs to be removed or retrieved from the synaptic cleft (Kandel et al., 2021; Purves, 2018; Radian et al., 1986; Pacholczyk et al., 1991). Curiously, several molecules widely accepted as neurotransmitters only meet some, rather than all, of these criteria (Curtis and Watkins, 1960; Felix and Künzle, 1974). Accurately detecting candidate molecules within synaptic vesicles could represent a significant step towards identifying neurotransmitters with a higher certainty.

Now, in eLife, Yi Rao and colleagues at Peking University and other research centers in Beijing – including Xiling Bian, Jiemin Zhu and Xiaobo Jia as joint first authors – report data that potentially uncovers a new neurotransmitter within the mammalian brain (Bian et al., 2023). The researchers used a combination of mass spectrometry, genetics, biochemistry, immunostaining, electrophysiology, and electron microscopy to support this conclusion.

Starting with purified synaptic vesicles (SV) from mouse brains, Bian et al. detected several well-known neurotransmitters in their samples, as well as creatine. The levels of SV creatine were higher than those of other known neurotransmitters, such as acetylcholine and serotonin, but lower than glutamate and gamma-aminobutyric acid (GABA). It has been known for decades that creatine is involved in recycling ATP in both muscle and brain tissue (Wyss and Kaddurah-Daouk, 2000; Brosnan and Brosnan, 2007; Wallimann et al., 2011). And more recently, researchers have suggested that it might also have additional roles in brain function (Ohtsuki et al., 2002; Braissant et al., 2011).

The next step was to dissect the molecular mechanism of creatine function in neurons. Bian et al. demonstrated that creatine was released from stimulated coronal brain slices. Interestingly, creatine release was reduced in slices from mice lacking either the gene that codes for an enzyme called AGAT (which is necessary for creatine production), or the gene that codes for the SLC6A8 creatine transporter. Importantly, the Bian et al. also observed that creatine has an inhibitory effect on a subset of neurons. They also found that SLC6A8 can move creatine into synaptosomes (isolated synaptic structures that contain a machine that helps release neurotransmitters and large numbers of synaptic vesicles). Collectively, these results are consistent with creatine acting like a neurotransmitter and with AGAT and SLC6A8 supporting that function (Figure 1).

Schematic illustration of the synthesis, transport and release of creatine in neurons.

A subtype of glial cell, known as an astrocyte (orange), likely synthesizes creatine molecules (red dots) through a process involving the amino acids glycine (Gly) and arginine (Arg), the enzymes AGAT and GAMT, and other compounds (GAA and SAM; Roschel et al., 2021). It is likely that the creatine molecules are then transported into a synaptic vesicle located in a presynaptic neuron that expresses a creatine transporter (CreaT) called SLC6A8. SNARE proteins (string-like structures) then mediate the release of the vesicles containing the creatine molecules into the synaptic cleft in a calcium-dependent manner, and the creatine molecules go on to bind to an as-yet unidentified creatine receptor (CreaR) on the postsynaptic neuron. It is possible that creatine molecules are also released directly by the astrocytes into the synaptic cleft between the neurons in a calcium-independent manner. AGAT: L-arginine: glycine amidinotransferase; GAA: guanidinoacetate; GAMT: guanidinoacetate methyltransferase; SAM: S-adenosylmethionine.

Image created with BioRender.com.

The work by Bian et al. goes beyond previous studies, which posited that creatine could have neurotransmitter-like properties (Almeida et al., 2006; Peral et al., 2010). Nevertheless, questions remain for future work. Most notably, Bian et al. did not identify a specific postsynaptic receptor for creatine. The researchers speculate that there might be a metabotropic receptor (or receptors) for creatine (Figure 1). Another mystery is that most of the creatine release after high potassium stimulation occurs when there is no extracellular calcium present. This is not consistent with a neurotransmitter role for that portion of the release. Bian et al. speculate that astrocytes might be responsible because astrocytes contain high levels of an enzyme called GAMT, which is involved in the production of creatine. If this idea were correct, then astrocytic creatine could potentially serve a neuromodulatory role. One final puzzle is that AGAT and SLC6A8 are found in different cells in the brain. So if creatine were a neurotransmitter, it suggests a complex model of creatine being synthesized in one cell type and subsequently then transported to another cell type for release (Figure 1).

In summary, Bian et al. report that creatine is a possible neurotransmitter in the central nervous system and that it meets several textbook criteria for a neurotransmitter (Kandel et al., 2021; Purves, 2018). This is a potentially groundbreaking finding that could have implications for understanding brain function and neurotransmission. It may also open new areas of understanding Creatine Transporter Deficiency, which manifests as a collection of intellectual disabilities, language delays and other neurological disorders that are associated with defective SLC6A8 (Salomons et al., 2003).

References

    1. Benfenati F
    2. Agnati LF
    (1991)
    Communication and computation in the central nervous system
    Functional Neurology 6:202–209.
    1. Carlsson A
    2. Falck B
    3. Hillarp NA
    (1962)
    Cellular localization of brain monoamines
    Acta Physiologica Scandinavica 56:1–28.
  1. Book
    1. Kandel ER
    2. Koester JD
    3. Mack SH
    4. Siegelbaum SA
    (2021)
    Principles of Neural Sciences (6th Edition)
    McGraw-Hill.
    1. Lovinger DM
    (2008)
    Communication networks in the brain: neurons, receptors, neurotransmitters, and alcohol
    Alcohol Research & Health 31:196–214.
  2. Book
    1. Purves D
    (2018)
    Neuroscience
    New York: Oxford University Press.
    1. Radian R
    2. Bendahan A
    3. Kanner BI
    (1986)
    Purification and identification of the functional sodium- and chloride-coupled gamma-aminobutyric acid transport glycoprotein from rat brain
    The Journal of Biological Chemistry 261:15437–15441.

Article and author information

Author details

  1. Bhagaban Mallik

    Bhagaban Mallik is in the Department of Anatomy and Cell Biology, University of Iowa, Iowa City, United States

    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7637-3338
  2. C Andrew Frank

    C Andrew Frank is in the Department of Anatomy and Cell Biology, University of Iowa, Iowa City, United States

    For correspondence
    andy-frank@uiowa.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9599-421X

Publication history

  1. Version of Record published:

Copyright

© 2023, Mallik and Frank

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,125
    views
  • 324
    downloads
  • 0
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Bhagaban Mallik
  2. C Andrew Frank
(2023)
Central Nervous System: Is creatine a CNS neurotransmitter?
eLife 12:e91824.
https://doi.org/10.7554/eLife.91824

Further reading

    1. Neuroscience
    Katie Morris, Edita Bulovaite ... Mathew H Horrocks
    Research Article

    The concept that dimeric protein complexes in synapses can sequentially replace their subunits has been a cornerstone of Francis Crick’s 1984 hypothesis, explaining how long-term memories could be maintained in the face of short protein lifetimes. However, it is unknown whether the subunits of protein complexes that mediate memory are sequentially replaced in the brain and if this process is linked to protein lifetime. We address these issues by focusing on supercomplexes assembled by the abundant postsynaptic scaffolding protein PSD95, which plays a crucial role in memory. We used single-molecule detection, super-resolution microscopy and MINFLUX to probe the molecular composition of PSD95 supercomplexes in mice carrying genetically encoded HaloTags, eGFP, and mEoS2. We found a population of PSD95-containing supercomplexes comprised of two copies of PSD95, with a dominant 12.7 nm separation. Time-stamping of PSD95 subunits in vivo revealed that each PSD95 subunit was sequentially replaced over days and weeks. Comparison of brain regions showed subunit replacement was slowest in the cortex, where PSD95 protein lifetime is longest. Our findings reveal that protein supercomplexes within the postsynaptic density can be maintained by gradual replacement of individual subunits providing a mechanism for stable maintenance of their organization. Moreover, we extend Crick’s model by suggesting that synapses with slow subunit replacement of protein supercomplexes and long-protein lifetimes are specialized for long-term memory storage and that these synapses are highly enriched in superficial layers of the cortex where long-term memories are stored.

    1. Neuroscience
    John P Grogan, Matthias Raemaekers ... Sanjay G Manohar
    Research Article

    Motivation depends on dopamine, but might be modulated by acetylcholine which influences dopamine release in the striatum, and amplifies motivation in animal studies. A corresponding effect in humans would be important clinically, since anticholinergic drugs are frequently used in Parkinson’s disease, a condition that can also disrupt motivation. Reward and dopamine make us more ready to respond, as indexed by reaction times (RT), and move faster, sometimes termed vigour. These effects may be controlled by preparatory processes that can be tracked using electroencephalography (EEG). We measured vigour in a placebo-controlled, double-blinded study of trihexyphenidyl (THP), a muscarinic antagonist, with an incentivised eye movement task and EEG. Participants responded faster and with greater vigour when incentives were high, but THP blunted these motivational effects, suggesting that muscarinic receptors facilitate invigoration by reward. Preparatory EEG build-up (contingent negative variation [CNV]) was strengthened by high incentives and by muscarinic blockade, although THP reduced the incentive effect. The amplitude of preparatory activity predicted both vigour and RT, although over distinct scalp regions; frontal activity predicted vigour, whereas a larger, earlier, central component predicted RT. The incentivisation of RT was partly mediated by the CNV, though vigour was not. Moreover, the CNV mediated the drug’s effect on dampening incentives, suggesting that muscarinic receptors underlie the motivational influence on this preparatory activity. Taken together, these findings show that a muscarinic blocker impairs motivated action in healthy people, and that medial frontal preparatory neural activity mediates this for RT.